Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Liraglutide: Phase III data

In the Phase III LEAD-2 trial in 1,026 patients, all 3 doses of liraglutide met the primary endpoint of improved glucose control from

Read the full 234 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE